Is the New Approach in Inflammatory Bowel Disease Treat-to-Target?
Volume 12 ; Issue 1 ; in Month : (2021) Article No : 111
Vinod Kumar P
Inflammatory bowel disease is a chronic inflammatory disease of which the etiology is unknown. Ulcerative colitis and Crohn's disease are the two main entities of inflammatory bowel disease that are challenging clinicians. In addition to tumor necrosis factor blockers, this overview summarizes current and future new drugs, in the treatment of inflammatory bowel disease according to their goals. The infiltration of lymphocytes into the intestinal lining is a target for therapeutic purposes in inflammatory bowel disease. The vascular cell adhesion molecule-1 and the mucosal addressin cell adhesion molecule-1 are a family of integrins for the alpha4 that are specifically expressed in the alimentary canal on vascular endothelial cells. In Crohn's disease, the alpha4beta7 integrin, and its endothelial receptor, the mucosal addressin cell adhesion molecule-1, have proven to be a relevant factor in the development of chronic intestinal inflammation. New biological and chemical drugs are emerging, with additional molecules pending approval.
Full Text Attachment
Views : 7 Downloads : 0